Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2012

View Archived Issues

GlaxoSmithKline reviews second quarter 2012

Alla Chem patents novel receptor ligands

Curagenix synthesizes new inhibitors of Wnt signaling

New phase I-II data disclosed on renal cell carcinoma vaccine candidate

Genetically corrected human iPSC-derived mesoangioblast as potential muscular dystrophy therapy

Three-peptide vaccine for advanced esophageal cancer shows promise in phase I-II trials

New complement factor D inhibitors prepared at Novartis

Kinentia Biosciences presents new ERK-2/MMP-1 inhibitors

Eisai discloses new BACE1 inhibitors

Microbiotix receives grant to develop type III secretion inhibitors

OrPro Therapeutics awarded NIH grant to advance recombinant thioredoxin

BMS-986094 administration suspended in clinical trial

BromSite advances to phase III testing

Agios Pharmaceuticals divulges novel PKM2 activators

Hologic completes acquisition

BioTime subsidiary receives grant from Israeli government

Novel DLL4-directed antibodies reported

FDA accepts Bronchitol NDA for review

Novel antibodies designed by researchers in Cuba and Uruguay

First patients treated in two lung cancer trials evaluating ganetespib

Two investigator-sponsored cabozantinib trials begin

Asterand changes name

Diffusion Pharmaceuticals completes treatment in first cohort of phase I/II brain cancer trial

Studies of Cinryze/rHuPH20 combination placed on temporary hold

DBV Technologies kicks off phase IIb VIPES study

Acquisition of Human Genome Sciences complete

Additional funding supports development of Anthim

Oxygen Biotherapeutics and U.S. navy establish Oxycyte CRADA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...